Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina.

This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences between sexes at 6 weeks and 9 months after the procedure.

The primary endpoint (PEP) was overall mortality at 6 weeks, while the secondary endpoint (SEP) was a composite of all-cause mortality, type Q acute myocardial infarction, and culprit vessel revascularization at 9 months.

Out of the 18,867 assessed patients, 6851 were women (36%). The women were older, more frequently of African-American origin, and had higher rates of hypertension, diabetes, heart failure, previous stroke, or peripheral vascular disease. In contrast, they had lower rates of prior angioplasty or myocardial revascularization surgery, prior myocardial infarction, and smoking.

In coronary angiography, women had more findings of single-vessel disease, and less frequently received multivessel angioplasty.

Read also: IVUS in Femoropopliteal PCI: Should We Start Using It?

While there were no differences between the PEP and the SEP, women had higher rates of bleeding, vascular repair, and repeat diagnostic catheterization. 

Significant differences were also observed in health status (measured by a Self-Assessment Questionnaire); they presented worse health status at 6 weeks and at 9 months at the expense of higher frequency of angina, worse quality of life, and physical limitations.

Conclusion

Being female was a predictor of worse health status at 6 weeks and at 9 months after angioplasty.

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org

Original Title: Sex Differences in Health Status and Clinical Outcomes After Nonprimary Percutaneous Coronary Intervention.

Reference: Pranoti G. Hiremath et al. Circ Cardiovasc Interv. 2022;15:e011308.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...